Electrical Stimulation for Recovery of Hand Function in Chronic Stroke Survivors

Not Applicable

Completed

Conditions: Hemiparesis
Hemiplegia
Stroke

Interventions: Device: Electrical stimulator

Registration Number: NCT00891319

Lead Sponsor: MetroHealth Medical Center

Brief Summary: Impaired hand function is one of the most frequently persisting consequences of stroke. The purpose of this study is to compare two different treatments -- Contralataterally Controlled Functional Electrical Stimulation (CCFES) and Cyclic Neuromuscular Electrical Stimulation (cNMES) -- for improved recovery of hand function after stroke.

Detailed Description: Hemiparesis of the upper limb is one of the most serious and most common impairments resulting from stroke. Approximately 75% of the over 750,000 strokes that occur annually in the United States cause some degree of upper extremity paralysis. Approximately 65% of stroke survivors still cannot use their affected hand to assist with activities of daily living 6 months after their stroke. The impact of upper extremity impairments on disability and health is great, yet there are relatively few rehabilitation interventions designed to restore function to the impaired upper limb. Therefore, our long-term objective is to develop upper extremity rehabilitation therapies that are effective at restoring arm and hand function, that are applicable across a wide range of impairment severity, and that are readily implemented in the present healthcare environment.

The purpose of this study is to estimate the efficacy of Contralataterally Controlled Functional Electrical Stimulation (CCFES) in reducing upper extremity impairment and activity limitation in chronic upper extremity hemiplegia. CCFES is a rehabilitation intervention in which neuromuscular electrical stimulation (NMES) is applied to the finger and thumb extensor muscles of the paretic upper limb to open the hand. The stroke survivor controls the stimulation intensity, and consequent degree of hand opening, by modulating the degree of opening of the contralateral unimpaired hand, which is detected by an instrumented glove. Thus, volitional opening of the unaffected hand produces stimulated opening of the affected hand. The stimulation paradigm is used to assist the stroke survivor in practicing functional tasks with their affected hand. We will conduct a randomized controlled trial in which chronic stroke survivors (\>6 months post-stroke) will be randomly assigned to receive 12 weeks of CCFES or cyclic NMES, an intervention that provides electrical stimulation of the hand extensors, but with preprogrammed timing and intensity. Randomization will be stratified on two levels of baseline hand impairment defined by the degree of voluntary finger extension present. Assessments of upper extremity impairment and activity limitation will be made every 3 weeks during the treatment period and every 2 months during a 6-month follow-up period.

This study is the first randomized controlled trial of CCFES in chronic upper extremity hemiplegia. Ultimately, the information learned in this study will serve to accelerate the development of treatments for reducing post-stroke disability.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 80

Inclusion Criteria

Age 18-80
> 6 months of first hemorrhagic or nonhemorrhagic stroke
Able to recall 2 of 3 items after 30 minutes
MRC ≤ 4 for finger extensors on paretic side
Able to follow 3-stage commands
Functional movement of shoulder and elbow (e.g., can reach ¾ hand-to- mouth movement) of paretic side
Caregiver available to assist with device and compliance if needed
Skin intact on hemiparetic arm
Medically stable
Surface NMES trial opens hand without pain
Full volitional hand opening/closing of contralateral hand
Upper extremity hand section of FMA < 11/14
Able to hear and respond to stimulator/cue box auditory cues
Completed occupational therapy (no concomitant OT)

Exclusion Criteria

Lack of functional PROM of the wrist or fingers of affected side
Severe shoulder or hand pain (unable to position hand in the workspace without pain)
Uncontrolled seizure disorder
Insensate forearm and/or hand
Uncompensated hemi-neglect (extinguishing to double simultaneous stimulation)
Edema of the affected forearm and/or hand
History of cardiac arrhythmias with hemodynamic instability
Cardiac pacemaker or other implanted electronic system
Pregnant
IM Botox injections in any UE muscle in the last 3 months
Parkinson's disease, SCI, TBI, or MS
Ipsilateral motor neuron lesion

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
cNMES	Electrical stimulator	cNMES - Cyclic NeuroMuscular Electrical Stimulation * Electrical stimulator * Preprogrammed cycles of finger and thumb extensor stimulation repeatedly and automatically open the hand. * Subject instructed to not move the contralateral arm/hand during stimulation. * Therapy sessions are done without the stimulation system.
CCFES	Electrical stimulator	CCFES - Contralaterally Controlled Functional Electrical Stimulation * Electrical stimulator * Stimulation to finger and thumb extensors only in response to, and with an intensity proportional to, opening of the contralateral unimpaired hand. * A glove instrumented with sensors and worn on the unimpaired hand detects the degree of hand opening and determines stimulation intensity. * Therapy sessions are done with the subject being assisted by the CCFES system.

Primary Outcome Measures

Name	Time	Method
Change in Box and Block Test Score at 6 Mo Post-Treatment	2 timepoints: Prior to treatment, and 6 months after completion of treatment.	The Box and Blocks test counts how many times the participant can pick up 1 block at t time, move it over a partition, and release it in a target area within 60 seconds. The minimum score is 0. There is no maximum score. The average score of healthy individuals within the age range of this study ranges from 70 to 79. Higher scores are considered to be a better outcome. For each individual, the score prior to treatment was subtracted from the score at 6 months after completion of treatment. Then for each treatment group, these change scores were averaged.

Secondary Outcome Measures

Name	Time	Method
Change in Upper Extremity Fugl-Meyer Score at 6-Months Post-Treatment	2 timepoints: Prior to treatment, and 6 months after completion of treatment.	The Upper Extremity Fugl-Meyer (UEFM) Assessment is a measure of upper limb motor impairment. Participants are asked to attempt to perform a list of very specific movements of the arm, elbow, forearm, wrist, and hand that take into account synergy patterns, isolated strength, coordination, and hypertonia. Each movement attempt is graded on a 3-point ordinal scale (0, cannot perform; 1, perform partially; and 2, perform fully) and these subscores are summed to provide a maximum score of 66, minimum score of 0. Higher scores are considered to be a better outcome. For each individual, the score prior to treatment was subtracted from the score at 6 months after completion of treatment. Then for each treatment group, these change scores were averaged.
Change in Arm Motor Abilities Test Score at 6-Month Post-Treatment	2 timepoints: Prior to treatment, and 6 months after completion of treatment.	The Arm Motor Abilities Test assesses the participant's ability to execute specific upper limb tasks and does not allow for compensation with the unimpaired side. The test consists of 9 compound tasks composed of 1 to 3 component tasks, each of which is rated on a 0 - 5 ordinal scale: 0, no attempt to use affected limb; 1, attempt to use affected limb but it does not participate functionally; 2, affected limb is used only as a helper or stabilizer; 3, affected limb is used slowly or within synergy patterns; 4, almost normal use of affected limb; 5, normal use. The final score is the average of all component task scores across all 9 compound tasks. The minimum score is 0; maximum score is 5. Higher scores are considered to be a better outcome. For each individual, the score prior to treatment was subtracted from the score at 6 months after completion of treatment. Then for each treatment group, these change scores were averaged.